Orphazyme deputy chair thinks layoffs could be option after EU disappointment

Biotech company Orphazyme has enough money to survive for a few months following the news of an expected rejection of the company’s drug hope arimoclomol by the EMA’s expert committee, the CHMP. Deputy Chair Bo Jesper Hansen still has hopes for the company’s chances in the US.

Bo Jesper Hansen has been on the board of Orphazyme since 2010, and has witnessed the company go through both ups and downs | Photo: Kåre Viemose

”Just disappointing.”

This is how Bo Jesper Hansen, biotech company Orphazyme’s deputy chairman, describes what looks to be a rejection of the company’s candidate, arimoclomol, from the CHMP, the expert committee for European Medicines Agency (EMA).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs